From the first reported cases of HIV in 1981 to the latest breakthroughs in long-acting prevention, this Spotlight timeline traces key moments in the global and South African response to the virus. It highlights scientific milestones, political controversies, activism, and the human stories that shaped one of the most significant public health challenges of our time.
Spotlight has launched a new HIV dashboard and graph generator based on outputs from the Thembisa model. Our hope is that this dashboard will help the public and people working in healthcare to find important HIV numbers more easily. Please take a look and let us know what you think of it.
An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa’s medicines regulator. The approval helps to clear the way for a limited public sector rollout of the “game-changing” shot set to start in April 2026.
A dire picture for HIV/Aids funding emerged at the 12th South African AIDS Conference, raising the call for resilience, adapting and also for government to raise its game, reports Ufrieda Ho.
A new HIV prevention jab has the potential to bring an end to the AIDS epidemic. But a lack of ambition and unjustifiable secrecy over pricing is holding it back, argue three leading health activists.
The health department has plans to roll out lenacapavir, a twice-yearly HIV prevention injection, in a select group of public sector clinics by April 2026. Meanwhile, little progress has been made towards rolling out a two-monthly prevention injection, despite the four-year head start this product had on lenacapavir. Catherine Tomlinson reports.
An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Elri Voigt reports on new findings on the pill that were presented at the International AIDS Conference.
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Elri Voigt reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.
Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.
HIV prevention injections that can provide two, or even six, months of protection per shot have arguably been the biggest HIV story of the year. Ahead of World AIDS Day, Professor Francois Venter assesses the state of play and the critical next steps with these potentially game-changing new tools in the fight against HIV.
In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works. Elri Voigt goes over the new findings and unpacks the licenses that are expected to facilitate the availability of generic versions of the jab in over a hundred countries, including South Africa.
In South Africa, taking HIV treatment means taking one or more antiretroviral tablets a day. People in some other countries have the additional option of treatment in the form of two injections administered every two months. Elri Voigt unpacks why long-acting HIV treatment is not available in South Africa and asks why the push for HIV prevention jabs has been so much stronger than that for HIV treatment jabs.
